Multi-Analyte, Genetic, and Thrombogenic Markers of Atherosclerosis (MAGMA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01276678|
Recruitment Status : Unknown
Verified November 2013 by Kevin Bliden, LifeBridge Health.
Recruitment status was: Recruiting
First Posted : January 13, 2011
Last Update Posted : November 6, 2013
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
About 13 million people in the United States have coronary artery disease (CAD). It is the leading cause of death in both men and women.
Coronary artery disease (CAD) occurs when the blood vessels that supply blood to the heart muscle (the coronary arteries) become hardened and narrowed. The arteries harden and narrow due to buildup of fatty and calcified material called plaque on their inner walls. The buildup of plaque is also called atherosclerosis. This is a process which starts early in life, but can be influenced by multiple factors.
Several factors increase the risk of developing atherosclerosis. They include high blood pressure, smoking, diabetes, high cholesterol and being related to someone who had a heart attack or a stroke. The more risk factors you have, the greater the chance that you have severe atherosclerosis. Some of the risk factors cannot be modified, like age and family history of early heart disease. The influenceable factors include high blood pressure, high blood cholesterol, high blood sugar, cigarette smoking, overweight or obesity, and lack of physical activity.
Nevertheless, there are patients without any above mentioned risk factors who develop atherosclerosis. In addition to that, there are also patients with several risk factors who do not develop severe coronary artery disease.
According to research studies high blood levels of some substances in the blood (biochemical markers) as well as some genes in the DNA of our cells may be associated with an increased risk of developing CAD and faster progression of the disease.
The purpose of this study is to find a correlation between certain blood markers and growth of the plaques, regardless of the presence of the classic risk factors for atherosclerosis. If we prove our hypothesis we will be one step closer to predicting the extent of atherosclerosis by performing certain blood tests.
|Condition or disease|
|Coronary Artery Disease|
|Study Type :||Observational|
|Estimated Enrollment :||1300 participants|
|Official Title:||Multi-Analyte, Genetic, and Thrombogenic Markers of Atherosclerosis (The MAGMA STUDY)|
|Study Start Date :||June 2010|
|Estimated Primary Completion Date :||June 2014|
|Estimated Study Completion Date :||December 2014|
300 healthy controls free from any pharmacologic therapy
Suspected CAD - Cardiac Cathetrization
subject's ≥18 years undergoing coronary angiography (inpatient cohort)or who have undergone coronary angiography within 5 years
- severity of angiographically-defined coronary lesions as determined by comprehensive biomarker risk profile [ Time Frame: 1.5 years ]To develop a comprehensive biomarker risk profile that will correlate with the severity of angiographically-defined coronary lesions, independently of the classic risk factors for atherosclerosis.
- Genetic Components [ Time Frame: 5 years ]To evaluate the contribution of genetic components to the presence of coronary artery disease in association with environmental factors. Of interest is to see whether certain genes might accelerate atherosclerosis in subgroups like smokers, diabetics, obese subjects, or various ethnic groups
- Biomarker Profile [ Time Frame: 1.5 years ]To determine the difference in the biomarker profile between CAD patients, patients with no known angiographically identified disease and healthy volunteers.
- Drug treatment strategies [ Time Frame: 1.5 years ]To determine the effect of different drug treatment strategies on biomarker profile.
- Prediction Model [ Time Frame: 1.5 years ]To create prediction model for major CV events based on genetic and other nongenetic biomarkers.
- Verigene [ Time Frame: 1.5 years ]To demonstrate the utility of the Point-of-Care Verigene 2C19/CBS Nucleic Acid Assay for detecting CYP2C19 variants.
- Urinary 11-dehydro thromboxane B2 [ Time Frame: 1.5 years ]To determine an association between urinary 11-dehydro thromboxane B2 concentrations with the severity of angiographically-defined coronary lesions.
- Lp-PLA2 [ Time Frame: 1.5 years ]To determine the association between Lp-PLA2 and angiographically-defined coronary lesions.
- Association of low-density lipoproteins/β2-glycoprotein I (β2GPI) [ Time Frame: 1.5 years ]To determine the association between oxidized low-density lipoprotein (oxLDL)/ β2-glycoprotein I (β2GPI) complexes and angiographically-defined coronary lesions.
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
|Sampling Method:||Non-Probability Sample|
- Age ≥18 years
- Subjects scheduled for coronary angiography
- Subjects who have undergone coronary angiography within 5 years
- Female subjects who are pregnant
- Subjects who suffer currently from an acute infection
- Subjects, who have received an experimental drug or who gave a blood donation of ≥ 1 pint within 8 weeks prior to screening
- Subjects with any coagulation, bleeding or blood disorders
- Subjects who are undergoing treatment for neoplastic diseases
- Subjects with autoimmune disease or connective tissue disease
- Subjects with HIV or hepatitis C.
- Subjects with any abnormal laboratory value or physical finding that according to the investigator may interfere with the interpretation of the study results, be indicative of an underlying disease state, or compromise the safety of a potential subject
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01276678
|Contact: Kevin P Bliden, B.S. MBAemail@example.com|
|Contact: Tania B Gesheff, MSNfirstname.lastname@example.org|
|United States, Maryland|
|Sinai Center for Thrombosis Research||Recruiting|
|Baltimore, Maryland, United States, 21215|
|Contact: Kevin P Bliden, B.S. MBA 410-601-4795 email@example.com|
|Contact: Tania B Gesheff, MSN 4106014795 firstname.lastname@example.org|
|Principal Investigator:||Paul A Gurbel, M.D., FACC||Sinai Center for Thrombosis Research|
|Responsible Party:||Kevin Bliden, Sinai Center for Thrombosis Research Program Manager, LifeBridge Health|
|Other Study ID Numbers:||
|First Posted:||January 13, 2011 Key Record Dates|
|Last Update Posted:||November 6, 2013|
|Last Verified:||November 2013|
Coronary Artery Disease
Arterial Occlusive Diseases